Salomé Vilchez-Larrea

6PUBLICATIONS
15CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cheminformatics and quantitative structure-activity relationshipsMedical infection agents (incl. prions)ChemotherapyChemical and thermal processes in energy and combustion
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Dec 31, 2025
Application of Data-Centric Supervised Machine Learning to Predict Phenotypic Activity Against Clinically Relevant Stages of Trypanosoma cruzi.

Nicolás Pérez-Mauad, Lucas N Alberca, Alejandra C Schoijet

|Sep 14, 2024
Structure-Aided Computational Design of Triazole-Based Targeted Covalent Inhibitors of Cruzipain.

Juan Pablo Cerutti, Lucas Abreu Diniz, Viviane Corrêa Santos

|Dec 30, 2022
Trypanosoma cruzi PARP is enriched in the nucleolus and is present in a thread connecting nuclei during mitosis.

María Laura Kevorkian, Salomé C Vilchez Larrea, Silvia H Fernández Villamil

|Jan 21, 2022
Tankyrase inhibitors hinder Trypanosoma cruzi infection by altering host-cell signalling pathways.

Laura Lafon-Hughes, Silvia H Fernández Villamil, Salomé C Vilchez Larrea

|May 24, 2021
An AMP-activated protein kinase complex with two distinctive alpha subunits is involved in nutritional stress responses in Trypanosoma cruzi.

Tamara Sternlieb, Alejandra C Schoijet, Patricio D Genta

|Nov 10, 2020
PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors.

Valentina Perini, Michelle Schacke, Pablo Liddle

Pageof 1

Frequent Collaborators

3 joint publications

Guillermo Daniel Alonso

2 joint publications

Laura Lafon-Hughes

1 joint publications

Silvia H Fernández Villamil

1 joint publications

Nicolás Pérez-Mauad